logo
ProjectEnded

Phages against MDR Enterococcus faecium

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

Due to its multidrug resistance (MDR), Enterococcus faecium (Efm) poses a challenge to the healthcare system and renders most standard antibiotics useless. Bacteriophage (phage) therapy has resurfaced as a treatment strategy for bacterial infections due to increasing antibiotic resistance. Its advantages include specificity, low side effects and production costs, especially when used in combinati

Status
Closed
Location
Norway
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Phages against MDR Enterococcus faecium

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Phages against MDR Enterococcus faecium” is an infrastructure initiative, located in Norway. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Due to its multidrug resistance (MDR), Enterococcus faecium (Efm) poses a challenge to the healthcare system and renders most standard antibiotics useless. Bacteriophage (phage) therapy has resurfaced as a treatment strategy for bacterial infections due to increasing antibiotic resistance. Its advantages include specificity, low side effects and production costs, especially when used in combination with standard-of-care antibiotics. Phage therapy has been successful in compassionate use, but its wider implementation is hindered by a lack of knowledge on which antibiotics phages synergize and the mechanisms behind remain elusive. Our project is unique in that it aims to enable the use of conventional antibiotics in MDR Efm through phages. We want to explore which antibiotic classes phages synergize with, which survival strategies Efm uses against phages, and how host factors influence the ability of the antibiotic-phage combination to kill Efm. First, we will investigate phages' interaction with different antibiotic classes against Efm. We will explore the dynamics of phage-antibiotic combinations and whether they are additive, synergistic, or antagonistic. Second, potential phage survival strategies of Efm will be investigated. Additionally, membrane vesicles will be investigated as a potential survival strategy against phages, and their ability to act as a decoy and protect the bacterium from phages will be studied. Third, we will investigate the impact of host factors on the phage-antibiotic killing of Efm, to see whether they can enhance or suppress the phage-antibiotic killing. This approach will provide a deeper understanding of the phages-antibiotic interaction against MDR Efm strains, as well as potential survival systems of Efm which may also shed light on possible mitigation strategies. Overall, this approach has the potential to enable the use of standard-of-care drugs against MDR bacterial infections in general.

Location

Country

Norway

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Article published date

2025-10-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project